Skip to content
Cancer Prevention with Rapamycin episode artwork

Apr 17, 2023 2 min

Cancer Prevention with Rapamycin

from Oncotarget Hosted by Oncotarget Podcast

A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “Cancer prevention with rapamycin.” The mTOR (Target of Rapamycin) pathway is involved in both cancer and aging. Furthermore, common cancers are age-related diseases, and their incidence increases exponentially with age. In his new research perspective, Mikhail V. Blagosklonny, M.D., Ph.D., from Roswell Park Comprehensive Cancer Center discusses rapamycin and other rapalogs and their potential to delay cancer by targeting pre-cancerous cells and slowing down organismal aging. “Rapamycin (sirolimus) and other rapalogs (everolimus) are anti-cancer and anti-aging drugs, which delay cancer by directly targeting pre-cancerous cells and, indirectly, by slowing down organism aging.” Cancer is an age-related disease and, figuratively, by slowing down time (and aging), rapamycin may delay cancer. In several dozen murine models, rapamycin robustly and reproducibly prevents cancer. Rapamycin slows cell proliferation and tumor progression, thus delaying the onset of cancer in carcinogen-treated, genetically cancer-prone and normal mice. Data on the use of rapamycin and everolimus in organ-transplant patients are consistent with their cancer-preventive effects. Treatment with rapamycin was proposed to prevent lung cancer in smokers and former smokers. Clinical trials in high-risk populations are warranted. “Currently, an increasing number of healthy people use rapamycin off-label to slow down aging. Perhaps in ten or twenty years from now, data will accumulate for retrospective analysis of cancer-prevention with rapamycin in humans.” DOI: https://doi.org/10.18632/oncotarget.28410 Correspondence to: Mikhail V. Blagosklonny - [email protected], [email protected] Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28410 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - chemoprevention, lung, rapamycin, aging, cancer About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact [email protected] 18009220957

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Cancer Prevention with Rapamycin

0:00 2:45

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Oncotarget?

This episode is 2 minutes long.

When was this Oncotarget episode published?

This episode was published on April 17, 2023.

Can I download this Oncotarget episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.